AU2021370296A1 - Compounds,compositions and methods of use to treat bone fractures - Google Patents

Compounds,compositions and methods of use to treat bone fractures Download PDF

Info

Publication number
AU2021370296A1
AU2021370296A1 AU2021370296A AU2021370296A AU2021370296A1 AU 2021370296 A1 AU2021370296 A1 AU 2021370296A1 AU 2021370296 A AU2021370296 A AU 2021370296A AU 2021370296 A AU2021370296 A AU 2021370296A AU 2021370296 A1 AU2021370296 A1 AU 2021370296A1
Authority
AU
Australia
Prior art keywords
compound
bone
amino acid
seq
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021370296A
Other languages
English (en)
Other versions
AU2021370296A9 (en
Inventor
Philip S. Low
Stewart LOW
Jeffery Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2021370296A1 publication Critical patent/AU2021370296A1/en
Publication of AU2021370296A9 publication Critical patent/AU2021370296A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021370296A 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat bone fractures Pending AU2021370296A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105669P 2020-10-26 2020-10-26
US63/105,669 2020-10-26
US202163193748P 2021-05-27 2021-05-27
US63/193,748 2021-05-27
PCT/US2021/047824 WO2022093373A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat bone fractures

Publications (2)

Publication Number Publication Date
AU2021370296A1 true AU2021370296A1 (en) 2023-06-22
AU2021370296A9 AU2021370296A9 (en) 2024-09-12

Family

ID=81383093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021370296A Pending AU2021370296A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat bone fractures

Country Status (7)

Country Link
US (1) US20230399374A1 (https=)
EP (1) EP4232074A4 (https=)
JP (1) JP2024506435A (https=)
AU (1) AU2021370296A1 (https=)
CA (1) CA3194776A1 (https=)
MX (1) MX2023004796A (https=)
WO (1) WO2022093373A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093374A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat spinal fusions
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
CN117373681B (zh) * 2023-10-30 2024-04-26 中国航天科工集团七三一医院 一种基于血糖调节系统作用的骨折愈合仿真方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883707A1 (en) * 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232285A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093374A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat spinal fusions

Also Published As

Publication number Publication date
EP4232074A4 (en) 2025-03-05
WO2022093373A1 (en) 2022-05-05
CA3194776A1 (en) 2022-05-05
JP2024506435A (ja) 2024-02-14
AU2021370296A9 (en) 2024-09-12
MX2023004796A (es) 2023-07-18
EP4232074A1 (en) 2023-08-30
US20230399374A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US20230399374A1 (en) Compounds, Compositions and Methods of Use to Treat Bone Fractures
JP7059195B2 (ja) Ｐｔｈプロドラッグ
JP7434419B2 (ja) ピーク対トラフ比が小さいｐｔｈ化合物
EP4275677B1 (en) Dosage regimen for a controlled-release pth compound
EP2054050B1 (en) Treatment of cartilage disorders with fgf-18
AU2017367699B2 (en) Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
CA2449686A1 (en) Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
US7820179B2 (en) Pegylated PTH as PTH receptor modulators and uses thereof
NZ574216A (en) Treatment of cartilage disorders with fgf-18
CN110139665A (zh) 包含其中骨组织选择性肽与甲状旁腺激素(pth)或其片段结合的融合肽的药物组合物和生物材料
Low et al. An engineered dual function peptide to repair fractured bones
CN116801900A (zh) 用于治疗骨折的化合物、组合物和使用方法
EP2168602A1 (en) Site-specific pegylated linear salmon calcitonin derivatives
US20240156973A1 (en) Osteotropic compositions and uses thereof
CN116710068A (zh) 用于治疗脊柱融合的化合物、组合物和方法
JP2007521268A (ja) カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法

Legal Events

Date Code Title Description
SREP Specification republished